229 related articles for article (PubMed ID: 8141105)
1. Efficacy of oral ondansetron, a selective antagonist of 5-HT3 receptors, in the treatment of nausea and vomiting associated with cyclophosphamide-based chemotherapies. Ondansetron Study Group.
Cubeddu LX; Pendergrass K; Ryan T; York M; Burton G; Meshad M; Galvin D; Ciociola AA
Am J Clin Oncol; 1994 Apr; 17(2):137-46. PubMed ID: 8141105
[TBL] [Abstract][Full Text] [Related]
2. A randomized, double-blind, placebo-controlled study evaluating the efficacy of combination olanzapine, ondansetron and dexamethasone for prevention of chemotherapy-induced nausea and vomiting in patients receiving doxorubicin plus cyclophosphamide.
Tienchaiananda P; Nipondhkit W; Maneenil K; Sa-Nguansai S; Payapwattanawong S; Laohavinij S; Maneechavakajorn J
Ann Palliat Med; 2019 Sep; 8(4):372-380. PubMed ID: 31500422
[TBL] [Abstract][Full Text] [Related]
3. Efficacy of ondansetron tablets in the management of chemotherapy-induced emesis: review of clinical trials.
Beck TM
Semin Oncol; 1992 Dec; 19(6 Suppl 15):20-5. PubMed ID: 1485178
[TBL] [Abstract][Full Text] [Related]
4. Oral ondansetron 8 mg twice daily is as effective as 8 mg three times daily in the prevention of nausea and vomiting associated with moderately emetogenic cancer chemotherapy. S3A-376 Study Group.
Beck TM; York M; Chang A; Navari R; Harvey WH; Meshad M; Griffin D; Wentz A
Cancer Invest; 1997; 15(4):297-303. PubMed ID: 9246149
[TBL] [Abstract][Full Text] [Related]
5. Efficacy of oral ondansetron in the prevention of emesis in outpatients receiving cyclophosphamide-based chemotherapy. The Ondansetron Study Group.
Beck TM; Ciociola AA; Jones SE; Harvey WH; Tchekmedyian NS; Chang A; Galvin D; Hart NE
Ann Intern Med; 1993 Mar; 118(6):407-13. PubMed ID: 8439113
[TBL] [Abstract][Full Text] [Related]
6. Oral ondansetron in the prophylaxis of nausea and vomiting induced by cyclophosphamide, methotrexate and 5-fluorouracil (CMF) in women with breast cancer. Results of a prospective, randomized, double-blind, placebo-controlled study.
Buser KS; Joss RA; Piquet D; Aapro MS; Cavalli F; Haefliger JM; Jungi WF; Bauer J; Obrist R; Brunner KW
Ann Oncol; 1993 Jun; 4(6):475-9. PubMed ID: 8353089
[TBL] [Abstract][Full Text] [Related]
7. A randomized double-blind comparison of ondansetron and metoclopramide in the prophylaxis of emesis induced by cyclophosphamide, fluorouracil, and doxorubicin or epirubicin chemotherapy.
Bonneterre J; Chevallier B; Metz R; Fargeot P; Pujade-Lauraine E; Spielmann M; Tubiana-Hulin M; Paes D; Bons J
J Clin Oncol; 1990 Jun; 8(6):1063-9. PubMed ID: 2140854
[TBL] [Abstract][Full Text] [Related]
8. Comparable safety and antiemetic efficacy of a brief (30-second bolus) intravenous granisetron infusion and a standard (15-minute) intravenous ondansetron infusion in breast cancer patients receiving moderately emetogenic chemotherapy.
Perez EA; Lembersky B; Kaywin P; Kalman L; Yocom K; Friedman C
Cancer J Sci Am; 1998; 4(1):52-8. PubMed ID: 9467047
[TBL] [Abstract][Full Text] [Related]
9. Antagonism of serotonin S3 receptors with ondansetron prevents nausea and emesis induced by cyclophosphamide-containing chemotherapy regimens.
Cubeddu LX; Hoffman IS; Fuenmayor NT; Finn AL
J Clin Oncol; 1990 Oct; 8(10):1721-7. PubMed ID: 2145400
[TBL] [Abstract][Full Text] [Related]
10. Prevention of delayed chemotherapy-induced nausea and vomiting after moderately high to highly emetogenic chemotherapy: comparison of ondansetron, prochlorperazine, and dexamethasone.
Lindley C; Goodin S; McCune J; Kane M; Amamoo MA; Shord S; Pham T; Yowell S; Laliberte K; Schell M; Bernard S; Socinski MA
Am J Clin Oncol; 2005 Jun; 28(3):270-6. PubMed ID: 15923800
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of three oral dosages of ondansetron in the prevention of nausea and emesis associated with cyclophosphamide-doxorubicin chemotherapy.
Fraschini G; Ciociola A; Esparza L; Templeton D; Holmes FA; Walters RS; Hortobagyi GN
J Clin Oncol; 1991 Jul; 9(7):1268-74. PubMed ID: 1828499
[TBL] [Abstract][Full Text] [Related]
12. Single 8 mg dose of oral ondansetron failed to prevent FAC chemotherapy-induced acute nausea and vomiting.
Bosnjak SM; Neskovic-Konstantinovic ZB; Jovanovic-Micic DJ; Mitrovic LB; Radulovic SS
J Chemother; 1996 Aug; 8(4):315-8. PubMed ID: 8873840
[TBL] [Abstract][Full Text] [Related]
13. Amisulpride prevents nausea and vomiting associated with highly emetogenic chemotherapy: a randomised, double-blind, placebo-controlled, dose-ranging trial.
Herrstedt J; Summers Y; Jordan K; von Pawel J; Jakobsen AH; Ewertz M; Chan S; Naik JD; Karthaus M; Dubey S; Davis R; Fox GM
Support Care Cancer; 2019 Jul; 27(7):2699-2705. PubMed ID: 30488222
[TBL] [Abstract][Full Text] [Related]
14. Ondansetron for nausea and vomiting associated with moderately emetogenic cancer chemotherapy.
DiBenedetto J; Cubeddu LX; Ryan T; Kish JA; Sciortino D; Beall C; Eisenberg PD; Henderson C; Griffin D; Wentz A
Clin Ther; 1995; 17(6):1091-8. PubMed ID: 8750400
[TBL] [Abstract][Full Text] [Related]
15. Randomized double-blind crossover ondansetron-dexamethasone versus ondansetron-placebo study for the treatment of chemotherapy-induced nausea and vomiting in pediatric patients with malignancies.
Alvarez O; Freeman A; Bedros A; Call SK; Volsch J; Kalbermatter O; Halverson J; Convy L; Cook L; Mick K
J Pediatr Hematol Oncol; 1995 May; 17(2):145-50. PubMed ID: 7749764
[TBL] [Abstract][Full Text] [Related]
16. Ondansetron suppository: a randomised, double-blind, double-dummy, parallel-group comparison with oral ondansetron for the prevention of cyclophosphamide-induced emesis and nausea. The Ondansetron Suppository emesis study group.
Davidson NG; Paska W; Van Belle S; Goedhals L; McQuade B; McRae J
Oncology; 1997; 54(5):380-6. PubMed ID: 9260599
[TBL] [Abstract][Full Text] [Related]
17. Phase III trial of casopitant, a novel neurokinin-1 receptor antagonist, for the prevention of nausea and vomiting in patients receiving moderately emetogenic chemotherapy.
Herrstedt J; Apornwirat W; Shaharyar A; Aziz Z; Roila F; Van Belle S; Russo MW; Levin J; Ranganathan S; Guckert M; Grunberg SM
J Clin Oncol; 2009 Nov; 27(32):5363-9. PubMed ID: 19805683
[TBL] [Abstract][Full Text] [Related]
18. Comparison of single-dose oral granisetron versus intravenous ondansetron in the prevention of nausea and vomiting induced by moderately emetogenic chemotherapy: a multicenter, double-blind, randomized parallel study.
Perez EA; Hesketh P; Sandbach J; Reeves J; Chawla S; Markman M; Hainsworth J; Bushnell W; Friedman C
J Clin Oncol; 1998 Feb; 16(2):754-60. PubMed ID: 9469367
[TBL] [Abstract][Full Text] [Related]
19. Efficacy of ginger for prophylaxis of chemotherapy-induced nausea and vomiting in breast cancer patients receiving adriamycin-cyclophosphamide regimen: a randomized, double-blind, placebo-controlled, crossover study.
Thamlikitkul L; Srimuninnimit V; Akewanlop C; Ithimakin S; Techawathanawanna S; Korphaisarn K; Chantharasamee J; Danchaivijitr P; Soparattanapaisarn N
Support Care Cancer; 2017 Feb; 25(2):459-464. PubMed ID: 27714530
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and tolerability of aprepitant for the prevention of chemotherapy-induced nausea and vomiting in patients with breast cancer after moderately emetogenic chemotherapy.
Warr DG; Hesketh PJ; Gralla RJ; Muss HB; Herrstedt J; Eisenberg PD; Raftopoulos H; Grunberg SM; Gabriel M; Rodgers A; Bohidar N; Klinger G; Hustad CM; Horgan KJ; Skobieranda F
J Clin Oncol; 2005 Apr; 23(12):2822-30. PubMed ID: 15837996
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]